Navigation Links
Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance
Date:1/28/2010

3.6 million at October 3, 2009. The decrease includes $15.0 million spent to acquire certain assets of StockerYale, Inc.

"There were a number of positive takeaways from the first quarter, including increasing sales, a return to profitability, good cash generation and very healthy bookings. Orders were up significantly over the prior year period in all four markets. We are particularly pleased with orders of approximately $22 million for our Coherent Equinox™ solar production tools, which are scheduled for delivery during fiscal 2010," said John Ambroseo, Coherent's President and Chief Executive Officer. "Given our backlog and outlook, we are raising our fiscal 2010 projection for net sales to $525 to $550 million.  To achieve this targeted range, we are ramping production capacity and unwinding the temporary cost containment measures implemented during fiscal 2009," he added.

"I am also pleased to report that we are making good progress on our product initiatives.  The customer qualifications of the DIAMOND™ E-1000 sealed CO2 laser is progressing as planned and we will begin revenue shipments in our third fiscal quarter.  We have further enhanced our scientific product portfolio with high performance devices to address new applications in physics and chemistry.  We also continue to proliferate our OPSL platform with the introduction of the Verdi™ G7, which supports a number of applications in the research market, as well as wavelength extensions of the Genesis™ series for use in the OEM components and instrumentation market," Ambroseo said.

BUSINESS OUTLOOK

With the strong customer order demand Coherent experienced in its first fiscal quarter, the Company announced that it expects sales in its second fiscal quarter t
'/>"/>

SOURCE Coherent, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Coherent, Inc. to Webcast Third Fiscal Quarter 2008 Results
2. Coherent, Inc. Announces Termination of SEC Informal Inquiry
3. Coherent, Inc. to Webcast Fourth Fiscal Quarter 2007 Results
4. Coherent, Inc. Receives Expected Letter from NASDAQ
5. Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Medicago reports positive Phase I results for its avian flu pandemic vaccine
8. Neogen Reports 18% Increase in Net Income
9. EntreMed Reports Receipt of Third Quarter Royalty Payment
10. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... 2015 , ... The Global Supply Chain Resiliency Council was ... practitioners with luminaries and thought leaders to advance the professional discipline through opportunities ... and performance excellence. At that time its principle sponsor, Resilinc , stated ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced the ... Growth, Trends & Forecasts (2014-2020)" report to their ... is estimated at $0.17 billion by 2018 at a ... The near future will bring Biomedical sensors that are ... sensors can be set to trigger alerts when unpredictable ...
(Date:8/31/2015)...  For people with Down syndrome, news from ... company, located in the Science + Technology Park at ... therapies yet for people with Down syndrome and other chromosome ... syndrome and Edwards syndrome aneuploidies in human cell cultures, ... Elixirgen plans to develop this technology into a treatment ...
(Date:8/31/2015)... HAYWARD, Calif. and SHANGHAI ... Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, ... Phase 2 clinical study for its lead drug ... designed to treat drug-resistant bacteria such as MRSA ... safer and better tolerated therapeutic option than currently ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... scientists at the University of California at Berkeley ... viruses called M13 phages to serve as structural ... of properties. By controlling the physical environment ... into hierarchically organized thin-film structures, with complexity that ...
... 19,  2011 Amylin Pharmaceuticals, Inc., ... (NYSE: LLY ) today announced that the U.S. ... for BYETTA® (exenatide) injection. BYETTA is now approved as an ... a thiazolidinedione (TZD), in conjunction with diet and exercise for ...
... Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. ... Annual BIO Investor Forum.  Hosted by the Biotechnology Industry Organization ... and emerging public companies. The meeting will take place October ... Chain will be presenting on October 26th at 1:30 p.m. ...
Cached Biology Technology:Manufacturing goes viral 2Manufacturing goes viral 3Manufacturing goes viral 4BYETTA® Approved for Use with Insulin Glargine in the U.S. 2BYETTA® Approved for Use with Insulin Glargine in the U.S. 3BYETTA® Approved for Use with Insulin Glargine in the U.S. 4BYETTA® Approved for Use with Insulin Glargine in the U.S. 5BYETTA® Approved for Use with Insulin Glargine in the U.S. 6BYETTA® Approved for Use with Insulin Glargine in the U.S. 7BYETTA® Approved for Use with Insulin Glargine in the U.S. 8Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum 2Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum 3
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ... Arabia Biomedical Sensors Market - Growth, Trends & Forecasts ... The Saudi Arabia Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/24/2015)... 24, 2015  Based on its recent analysis of the ... 2015 African Biometrics Company of the Year Award. DERMALOG is ... success in Africa . It has particularly ... has implemented one of the largest biometric mass applications in ... the Central Bank of Nigeria with ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... Calif. How much calcium could a hibernating woodchuck,s ... could sequester calcium? More than enough, it turns out, ... heart rhythms such as ventricular tachycardia and ventricular fibrillation ... to a new study of the hibernating animals that ...
... eluded vaccine-makers for thirty years, in part due to ... clinical virologists from the Massachusetts Institute of Technology (MIT) ... a promising strategy for vaccine design using a mathematical ... to quantum physics, as well as in analyses of ...
... restaurant menus might meet federal labeling requirements but don,t do ... meal choices, a new Columbia University School of Nursing (CUSON) ... NP, DNSc, assistant professor of nursing at CUSON, and colleagues, ... Journal of Urban Health . The researchers studied the calorie ...
Cached Biology News:Woodchucks and sudden cardiac death 2Vaccines for HIV: A new design strategy 2Fast-food menu calorie counts legally compliant but not as helpful to consumers as they should be 2Fast-food menu calorie counts legally compliant but not as helpful to consumers as they should be 3
... SARA ( Abpromise for all tested ... peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding ... (Drosophila melanogaster) SARA. Conserved sequence unique ... ID: 9372 Swiss ...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: